The financials
Maravai LifeSciences Holdings, Inc. by the numbers
Maravai LifeSciences Holdings, Inc. (MRVI) reported revenue of $66M in Q1 2026 (quarter ended Mar 31, 2026), up 41% from the same quarter a year earlier. That came with a gross margin of 51% and net loss of $3.7M. For the full year FY2025, revenue was $186M (−28% year on year) and net income −$131M. Its largest region in Jun 2026 was United States at $31M, 47% of the disclosed total, ahead of North America at 38%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $66M | $47M | +41% |
| Gross profit | $34M | $7.7M | +336% |
| Operating income | −$2.2M | −$49M | n/a |
| Net income | −$3.7M | −$30M | n/a |
| Diluted EPS | −$0.02 | −$0.21 | n/a |
| Geographic | Revenue | Share |
|---|---|---|
| United States | $31M | 47% |
| North America | $25M | 38% |
| EMEA | $6.1M | 9.3% |
| Asia Pacific | $3.7M | 5.6% |
| Latin And Central America | $193K | 0.3% |
Business Segments
Revenue split by geographic segment, from SEC XBRL filings.
Latest period: Jun 2026Total $65.6M (-21%)
Latin And Central America grew +133% year on yearUnited States +2.0% year on year
Segment Latestquarter on quarteryear on year
- United States$30.9M$30.9MQoQ -12%year on year +2.0%-12%+2.0%
- North America$24.6M$24.6MQoQ -12%year on year +3.2%-12%+3.2%
- EMEA$6.1M$6.1MQoQ -65%year on year +49%-65%+49%
- Asia Pacific$3.7M$3.7MQoQ +94%year on year +22%+94%+22%
- Latin And Central America$193.0K$193.0KQoQ +133%year on year +133%+133%+133%